The potential role of IL‐33/ST2 signaling in fibrotic diseases

Review on the biological characteristics of IL‐33 and the role of the IL‐33/ST2 signaling pathway in various fibrotic diseases. IL‐33, a new member of the IL‐1F, is widely expressed throughout the body and can be up‐regulated by stimulation with proinflammatory factors. It has been identified as a f...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of leukocyte biology 2015-07, Vol.98 (1), p.15-22
Hauptverfasser: Gao, Qiaoyan, Li, Yan, Li, Mingcai
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 22
container_issue 1
container_start_page 15
container_title Journal of leukocyte biology
container_volume 98
creator Gao, Qiaoyan
Li, Yan
Li, Mingcai
description Review on the biological characteristics of IL‐33 and the role of the IL‐33/ST2 signaling pathway in various fibrotic diseases. IL‐33, a new member of the IL‐1F, is widely expressed throughout the body and can be up‐regulated by stimulation with proinflammatory factors. It has been identified as a functional ligand for the plasma membrane receptor complex that is a heterodimer consisting of membrane‐bound ST2L, which is a member of the IL‐1R family, and IL‐1RAcP. IL‐33 is crucial for the induction of Th2 immune responses. Additionally, under other circumstances, it can also act as an endogenous danger signal. Recently, many studies have demonstrated that IL‐33 may be related to the development and progression of fibrotic diseases. It has proinflammatory effects in some fibrotic diseases but has anti‐inflammatory effects in others. In this review, the biologic characteristics of IL‐33 and the role of the IL‐33/ST2 signaling pathway in various fibrotic diseases will be discussed. We hope this overview will provide new insights for the treatment of these diseases.
doi_str_mv 10.1189/jlb.3RU0115-012R
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1808637660</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1808637660</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4865-1f584ceeda880c9c1c692a8e7dac05c32721847fc2b13836e92bac51c90535323</originalsourceid><addsrcrecordid>eNqFkLtOwzAUhi0EouWyM6GMLCnn-MSOs3ERV0VCgjJbjuOAqzQpcSrExiPwjDwJQS2snf7l-7_hY-wIYYKostNZXUzo8RkQRQzIH7fYGDNSMcmUttkY0gRjkQCM2F4IMwAgLmGXjbhQavhnY3Y2fXXRou1d03tTR11bu6itorv8-_OL6PRpyqPgXxpT--Yl8k1U-aJre2-j0gdnggsHbKcydXCH691nz9dX08vbOH-4ubs8z2ObKClirIRKrHOlUQpsZtHKjBvl0tJYEJZ4ylElaWV5gaRIuowXxgq0GQgSxGmfnay8i659W7rQ67kP1tW1aVy7DBoVKEmplLAZlRmhSonjgMIKtV0bQucqvej83HQfGkH_JtZDYr1OrH8TD5fjtX1ZzF35f_hrOgBiBbz72n1sFOr7_AIABf0AvnmGeg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1693187321</pqid></control><display><type>article</type><title>The potential role of IL‐33/ST2 signaling in fibrotic diseases</title><source>Wiley Online Library - AutoHoldings Journals</source><source>MEDLINE</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Gao, Qiaoyan ; Li, Yan ; Li, Mingcai</creator><creatorcontrib>Gao, Qiaoyan ; Li, Yan ; Li, Mingcai</creatorcontrib><description>Review on the biological characteristics of IL‐33 and the role of the IL‐33/ST2 signaling pathway in various fibrotic diseases. IL‐33, a new member of the IL‐1F, is widely expressed throughout the body and can be up‐regulated by stimulation with proinflammatory factors. It has been identified as a functional ligand for the plasma membrane receptor complex that is a heterodimer consisting of membrane‐bound ST2L, which is a member of the IL‐1R family, and IL‐1RAcP. IL‐33 is crucial for the induction of Th2 immune responses. Additionally, under other circumstances, it can also act as an endogenous danger signal. Recently, many studies have demonstrated that IL‐33 may be related to the development and progression of fibrotic diseases. It has proinflammatory effects in some fibrotic diseases but has anti‐inflammatory effects in others. In this review, the biologic characteristics of IL‐33 and the role of the IL‐33/ST2 signaling pathway in various fibrotic diseases will be discussed. We hope this overview will provide new insights for the treatment of these diseases.</description><identifier>ISSN: 0741-5400</identifier><identifier>EISSN: 1938-3673</identifier><identifier>DOI: 10.1189/jlb.3RU0115-012R</identifier><identifier>PMID: 25881899</identifier><language>eng</language><publisher>United States</publisher><subject>cardiac fibrosis ; Fibrosis - metabolism ; hepatic fibrosis ; Humans ; Interleukin-1 Receptor-Like 1 Protein ; Interleukin-33 ; Interleukins - physiology ; pulmonary fibrosis ; Receptors, Cell Surface - physiology ; Receptors, Interleukin - metabolism ; Signal Transduction - physiology ; skin fibrosis</subject><ispartof>Journal of leukocyte biology, 2015-07, Vol.98 (1), p.15-22</ispartof><rights>2015 Society for Leukocyte Biology</rights><rights>Society for Leukocyte Biology.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4865-1f584ceeda880c9c1c692a8e7dac05c32721847fc2b13836e92bac51c90535323</citedby><cites>FETCH-LOGICAL-c4865-1f584ceeda880c9c1c692a8e7dac05c32721847fc2b13836e92bac51c90535323</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1189%2Fjlb.3RU0115-012R$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1189%2Fjlb.3RU0115-012R$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25881899$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gao, Qiaoyan</creatorcontrib><creatorcontrib>Li, Yan</creatorcontrib><creatorcontrib>Li, Mingcai</creatorcontrib><title>The potential role of IL‐33/ST2 signaling in fibrotic diseases</title><title>Journal of leukocyte biology</title><addtitle>J Leukoc Biol</addtitle><description>Review on the biological characteristics of IL‐33 and the role of the IL‐33/ST2 signaling pathway in various fibrotic diseases. IL‐33, a new member of the IL‐1F, is widely expressed throughout the body and can be up‐regulated by stimulation with proinflammatory factors. It has been identified as a functional ligand for the plasma membrane receptor complex that is a heterodimer consisting of membrane‐bound ST2L, which is a member of the IL‐1R family, and IL‐1RAcP. IL‐33 is crucial for the induction of Th2 immune responses. Additionally, under other circumstances, it can also act as an endogenous danger signal. Recently, many studies have demonstrated that IL‐33 may be related to the development and progression of fibrotic diseases. It has proinflammatory effects in some fibrotic diseases but has anti‐inflammatory effects in others. In this review, the biologic characteristics of IL‐33 and the role of the IL‐33/ST2 signaling pathway in various fibrotic diseases will be discussed. We hope this overview will provide new insights for the treatment of these diseases.</description><subject>cardiac fibrosis</subject><subject>Fibrosis - metabolism</subject><subject>hepatic fibrosis</subject><subject>Humans</subject><subject>Interleukin-1 Receptor-Like 1 Protein</subject><subject>Interleukin-33</subject><subject>Interleukins - physiology</subject><subject>pulmonary fibrosis</subject><subject>Receptors, Cell Surface - physiology</subject><subject>Receptors, Interleukin - metabolism</subject><subject>Signal Transduction - physiology</subject><subject>skin fibrosis</subject><issn>0741-5400</issn><issn>1938-3673</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkLtOwzAUhi0EouWyM6GMLCnn-MSOs3ERV0VCgjJbjuOAqzQpcSrExiPwjDwJQS2snf7l-7_hY-wIYYKostNZXUzo8RkQRQzIH7fYGDNSMcmUttkY0gRjkQCM2F4IMwAgLmGXjbhQavhnY3Y2fXXRou1d03tTR11bu6itorv8-_OL6PRpyqPgXxpT--Yl8k1U-aJre2-j0gdnggsHbKcydXCH691nz9dX08vbOH-4ubs8z2ObKClirIRKrHOlUQpsZtHKjBvl0tJYEJZ4ylElaWV5gaRIuowXxgq0GQgSxGmfnay8i659W7rQ67kP1tW1aVy7DBoVKEmplLAZlRmhSonjgMIKtV0bQucqvej83HQfGkH_JtZDYr1OrH8TD5fjtX1ZzF35f_hrOgBiBbz72n1sFOr7_AIABf0AvnmGeg</recordid><startdate>201507</startdate><enddate>201507</enddate><creator>Gao, Qiaoyan</creator><creator>Li, Yan</creator><creator>Li, Mingcai</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7T5</scope><scope>H94</scope></search><sort><creationdate>201507</creationdate><title>The potential role of IL‐33/ST2 signaling in fibrotic diseases</title><author>Gao, Qiaoyan ; Li, Yan ; Li, Mingcai</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4865-1f584ceeda880c9c1c692a8e7dac05c32721847fc2b13836e92bac51c90535323</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>cardiac fibrosis</topic><topic>Fibrosis - metabolism</topic><topic>hepatic fibrosis</topic><topic>Humans</topic><topic>Interleukin-1 Receptor-Like 1 Protein</topic><topic>Interleukin-33</topic><topic>Interleukins - physiology</topic><topic>pulmonary fibrosis</topic><topic>Receptors, Cell Surface - physiology</topic><topic>Receptors, Interleukin - metabolism</topic><topic>Signal Transduction - physiology</topic><topic>skin fibrosis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gao, Qiaoyan</creatorcontrib><creatorcontrib>Li, Yan</creatorcontrib><creatorcontrib>Li, Mingcai</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>Journal of leukocyte biology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gao, Qiaoyan</au><au>Li, Yan</au><au>Li, Mingcai</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The potential role of IL‐33/ST2 signaling in fibrotic diseases</atitle><jtitle>Journal of leukocyte biology</jtitle><addtitle>J Leukoc Biol</addtitle><date>2015-07</date><risdate>2015</risdate><volume>98</volume><issue>1</issue><spage>15</spage><epage>22</epage><pages>15-22</pages><issn>0741-5400</issn><eissn>1938-3673</eissn><abstract>Review on the biological characteristics of IL‐33 and the role of the IL‐33/ST2 signaling pathway in various fibrotic diseases. IL‐33, a new member of the IL‐1F, is widely expressed throughout the body and can be up‐regulated by stimulation with proinflammatory factors. It has been identified as a functional ligand for the plasma membrane receptor complex that is a heterodimer consisting of membrane‐bound ST2L, which is a member of the IL‐1R family, and IL‐1RAcP. IL‐33 is crucial for the induction of Th2 immune responses. Additionally, under other circumstances, it can also act as an endogenous danger signal. Recently, many studies have demonstrated that IL‐33 may be related to the development and progression of fibrotic diseases. It has proinflammatory effects in some fibrotic diseases but has anti‐inflammatory effects in others. In this review, the biologic characteristics of IL‐33 and the role of the IL‐33/ST2 signaling pathway in various fibrotic diseases will be discussed. We hope this overview will provide new insights for the treatment of these diseases.</abstract><cop>United States</cop><pmid>25881899</pmid><doi>10.1189/jlb.3RU0115-012R</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0741-5400
ispartof Journal of leukocyte biology, 2015-07, Vol.98 (1), p.15-22
issn 0741-5400
1938-3673
language eng
recordid cdi_proquest_miscellaneous_1808637660
source Wiley Online Library - AutoHoldings Journals; MEDLINE; Oxford University Press Journals All Titles (1996-Current); EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection
subjects cardiac fibrosis
Fibrosis - metabolism
hepatic fibrosis
Humans
Interleukin-1 Receptor-Like 1 Protein
Interleukin-33
Interleukins - physiology
pulmonary fibrosis
Receptors, Cell Surface - physiology
Receptors, Interleukin - metabolism
Signal Transduction - physiology
skin fibrosis
title The potential role of IL‐33/ST2 signaling in fibrotic diseases
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T06%3A55%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20potential%20role%20of%20IL%E2%80%9033/ST2%20signaling%20in%20fibrotic%20diseases&rft.jtitle=Journal%20of%20leukocyte%20biology&rft.au=Gao,%20Qiaoyan&rft.date=2015-07&rft.volume=98&rft.issue=1&rft.spage=15&rft.epage=22&rft.pages=15-22&rft.issn=0741-5400&rft.eissn=1938-3673&rft_id=info:doi/10.1189/jlb.3RU0115-012R&rft_dat=%3Cproquest_cross%3E1808637660%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1693187321&rft_id=info:pmid/25881899&rfr_iscdi=true